EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients

Last updated: January 7, 2026
Sponsor: Barts & The London NHS Trust
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chronic Pain

Spinal Surgery

Pain

Treatment

spinal cord stimulation

Clinical Study ID

NCT05704751
322831
  • Ages 18-75
  • All Genders

Study Summary

This study is designed to evaluate the feasibility of using intra-operative ECAP and Late-Response (LR) recordings for confirmation of activating the neuronal target of the dorsal column in a single-stage SCS lead placement procedure. The collected ECAP and LR data will be analysed post-hoc to further evaluate its utility for determining the laterality of lead placement with respect to the physiologic midline of the dorsal column.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Be 18-75 years of age or older at the time of enrolment.

  2. Symptoms of chronic predominant back pain for at least 6-months, with a minimum painintensity of 5/10 in the primary pain area on VAS pain intensity questionnaire.

  3. Be an appropriate candidate for the surgical procedures required in this study basedon the clinical judgment of the implanting physician.

  4. Be capable of subjective evaluation, able to read and understand English-writtenquestionnaires, and able to read, understand and sign the written inform consent inEnglish.

  5. Be willing and capable of giving informed consent.

  6. Be willing and able to comply with study-related requirements, procedures, andvisits.

Exclusion

Exclusion Criteria:

Have a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator.

  1. Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention, and/or ability to evaluate treatment outcomes.

  2. Subjects with chronic alcohol abuse or currently in rehabilitation. 4. Be benefitting within from an interventional procedure and/or surgery to treat chronic pain (Subjects should be enrolled at least 30 days from last benefit).

  3. Have prior experience with SCS. 6. Have an existing drug pump and/or another active implantable device such as a pacemaker.

  4. Have a condition currently requiring or likely to require the use of diathermy.

  5. Have an active systemic or local infection at the anticipated needle entry site.

  6. Be pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 2 years post-menopausal).

  7. Are currently nursing (if female).

  8. Be concomitantly participating in another clinical study.

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: spinal cord stimulation
Phase:
Study Start date:
October 27, 2023
Estimated Completion Date:
April 01, 2026

Study Description

The primary objectives of the study will be to evaluate the feasibility of using intra-operative ECAP and LR recordings for confirming the activation of the neural target of the dorsal column in a single-stage SCS lead placement procedure. The collected ECAP and LR data will be analysed post-hoc to further evaluate its utility for determining the laterality of lead placement with respect to the physiologic midline of the dorsal column. Change in pain intensity (Visual Analogue Scale = VAS) will be evaluated after 3-months of the targeted (primary) pain area.

Conventional open-loop SCS devices produce paraesthesia (a tingling sensation) that overlap the pain distribution, with the intent of masking pain perception. It is thought that conventional open-loop SCS success depends on adequacy and durability of paraesthesia coverage as well as patient tolerance of the induced sensations. For the last 40 years, the primary focus of innovation for SCS for chronic pain has been to improve the reliability of overlapping paraesthesia's with distribution of pain. Achieving adequate and stable paraesthesia coverage in the chronic pain region is known to be challenging, making back pain more difficult to treat and limiting application mostly to patients with predominant leg pain. Therefore, the use of neurostimulation for the treatment of chronic pain (especially back) shows mixed results. Declining efficacy over time has been observed in studies using low-frequency SCS programming.

Programming in the EVOKE Randomized Controlled Trial (RCT) study was performed using objective, neurophysiological feedback i.e., ECAPs for the first time since the advent of SCS to program both the control (open-loop) and test (closed-loop) chronic low back and/or leg pain patients. The trial has shown the superior long-term efficacy and durability of closed-loop SCS in treatment of chronic back and leg pain. Unpublished data collected during the study showed that objective EVOKE ECAP-based programming does not require paraesthesia overlap with pain distribution to achieve successful outcomes in low back (axial or radicular) and leg pain patients. Evaluation of data demonstrated that at 12-months follow-up (EVOKE study), 27% of subjects did not report paraesthesia in the low back region and reported 82% and 72% back pain relief with closed-loop and open-loop SCS, respectively. This is compared to 75% and 69% pain relief, respectively, in subjects who reported paraesthesia. Therefore, no interaction between the treatment effect and paraesthesia (p = 0.775) exist (EVOKE study).

The secondary objective of this observational study is to evaluate the overlap of the dermatomal pain map with the paraesthesia coverage provided by ECAP-based programming by asking the patient to report how much percentage of the primary pain area is covered by paraesthesia.

Additionally, the patients will be followed-up for 12-months and treatment outcomes (Evaluate long-term clinical outcomes (PROMIS 29+2 Profile v2.1, VAS, long-term responders in terms of pain relief, subject satisfaction with asleep lead placement, stimulation programming characteristics, neurophysiological characteristics) will be captured pre-treatment at baseline, at 3-months, 6-months and 12-months post-activation and initial programming of the closed-loop Stimulator (CLS).

Connect with a study center

  • Barts Health NHS Trust

    London, EC1A 4NP
    United Kingdom

    Site Not Available

  • Barts Health NHS Trust

    London 2643743, EC1A 4NP
    United Kingdom

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.